The market rally fell Wednesday as Google dived, but it still looks healthy. Disney leads overnight earnings movers. Read More...
Benzinga
Analyst Reiterates This Alzheimer’s Candidate As Top Idea For 2023
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ: BTAI) from $24 to $38, with a Buy rating. Since the analyst’s previous model update last December, BTAI shares have meaningfully outperformed vs. its peers (+61% vs +8% for the XBI), based on increased bullishness ahead of the first Phase 3 data for lead asset Igalmi/BXCL501 in Alzheimer’s disease (AD) agitation (expected in 1H23). The analyst revisited the BTAI model based on BXCL501 in schizophrenia, bipolar disorder, AD, and
